Y-mAbs Therapeutics

Y-MABS THERAPEUTICS INC

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Price Action

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

COGT

NPCE

SLRN

THRD

TKNO

TSLA

YMAB

Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

hans-reniers-lQGJCMY5qcM-unsplash (2)

Biotech

General

Y-mAbs&#39; Omburtamab Failure: The Critical Turning Point And $19.65M Shareholder Settlement

Stein,,Switzerland,-,February,18,,2020:,Novartis,Is,The,Second

Analyst Color

Equities

Large Cap

Health Care

Analyst Ratings

ABBV

AMGN

BIIB

CATX

INCY

KYMR

REGN

Novartis aims to enhance Pluvicto&#39;s market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights

Y-mAbs Therapeutics Inc

Earnings

Press Releases

Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

Investing in Oncology: 4 Companies Driving Cancer Treatment Innovation

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting

Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025

Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)

Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025

Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

CADL

DAWN

OSTX

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Cardiff Oncology

Cargo Therapeutics

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Design Therapeutics

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Foghorn Therapeutics

Genfit

I-MAB

Immutep Limited - American Depositary Shares

Immutep

Inhibrx Biosciences

INmune Bio

Inozyme Pharma

Kodiak Sciences

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Monopar Therapeutics

Nuvectis Pharma

Prime Medicine

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Instil Bio

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Tevogen Bio Holdings

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

Oppenheimer

HC Wainwright & Co.

Truist Securities

B of A Securities

Morgan Stanley

Comments

Y-mAbs Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell